milategrast (E6007) / Eisai, University of Tsukuba - LARVOL DELTA

Eisai: Information Meeting 2014 (Eisai) - Anticipated submission in Japan for ulcerative colitis in FY 2018 or later

Anticipated Japanese regulatory • Inflammatory Bowel Disease

Study of E6007 in Japanese Patients With Moderate Active Ulcerative Colitis (clinicaltrials.gov) - P2; N=144; Recruiting; Sponsor: EA Pharma Co., Ltd.

New P2 trial • Biosimilar • Inflammatory Bowel Disease

Study of E6007 in Japanese Patients With Moderate Active Ulcerative Colitis (clinicaltrials.gov) - P2; N=144; Recruiting; Sponsor: EA Pharma Co., Ltd.; Trial completion date: Sep 2019 ➔ Mar 2019

Trial completion date • Biosimilar • Ulcerative Colitis

Study of E6007 in Japanese Patients With Moderate Active Ulcerative Colitis (clinicaltrials.gov) - P2; N=147; Completed; Sponsor: EA Pharma Co., Ltd.; Active, not recruiting ➔ Completed

Clinical • Trial completion

Study of E6007 in Japanese Patients With Moderate Active Ulcerative Colitis (clinicaltrials.gov) - P2; N=147; Active, not recruiting; Sponsor: EA Pharma Co., Ltd.; Trial completion date: Jun 2019 ➔ Sep 2019

Clinical • Trial completion date

Study of E6007 in Japanese Patients With Moderate Active Ulcerative Colitis (clinicaltrials.gov) - P2; N=147; Active, not recruiting; Sponsor: EA Pharma Co., Ltd.; Recruiting ➔ Active, not recruiting; Trial completion date: Mar 2019 ➔ Jun 2019

Clinical • Enrollment closed • Trial completion date